
Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C
Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Julie Khlevner, MD, AGAF, is Associate Professor of Pediatrics at Columbia University Medical Center and Chair, NASPGHAN Neurogastroenterology and Motility Committee.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.